Cargando…

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure

The aim of this analysis was to use a physiologically based pharmacokinetic (PBPK) model to predict the impact of changes in dissolution rates on elagolix exposures and define clinically relevant acceptance criteria for dissolution. Varying in vitro dissolution profiles were utilized in a PBPK model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukherjee, Dwaipayan, Chiney, Manoj S., Shao, Xi, Ju, Tzuchi R., Shebley, Mohamad, Marroum, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320978/ https://www.ncbi.nlm.nih.gov/pubmed/35405765 http://dx.doi.org/10.1002/bdd.2315

Ejemplares similares

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Chiney, Manoj S., et al.
Publicado: (2019)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
por: Beck, Denise, et al.
Publicado: (2021)

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis
por: Shebley, Mohamad, et al.
Publicado: (2019)

Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
por: Mukherjee, Dwaipayan, et al.
Publicado: (2018)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
por: Beck, Denise, et al.
Publicado: (2022)

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology
por: Weddell, Jared, et al.
Publicado: (2020)

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
por: Snabes, Michael C., et al.
Publicado: (2023)

Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?
por: Shebley, Mohamad
Publicado: (2018)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
por: Stodtmann, Sven, et al.
Publicado: (2021)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

A Clinician's Guide to the Treatment of Endometriosis with Elagolix
por: Leyland, Nicholas, et al.
Publicado: (2021)

Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse
por: Shebley, Mohamad, et al.
Publicado: (2018)

Elagolix in the treatment of endometriosis: impact beyond pain symptoms
por: Archer, David F., et al.
Publicado: (2020)

The role of elagolix in the suppression of ovulation in donor oocyte cycles
por: Boniface, Catherine, et al.
Publicado: (2023)

Elagolix: How far can it go in the world of gynecology?
por: Danis, Rachel B.
Publicado: (2023)

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix
por: Taylor, Hugh S., et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women
por: Feldman, Robert A., et al.
Publicado: (2021)

Physiologically Relevant In Vitro-In Vivo Correlation (IVIVC) Approach for Sildenafil with Site-Dependent Dissolution
por: Kim, Tae Hwan, et al.
Publicado: (2019)

Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations
por: Mukherjee, Dwaipayan, et al.
Publicado: (2023)

Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
por: Dun, Erica C., et al.
Publicado: (2017)

Does timing matter when initiating elagolix in a natural menstrual cycle?
por: Danis, Rachel B., et al.
Publicado: (2021)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

In Vivo Relevance of a Biphasic In Vitro Dissolution Test for the Immediate Release Tablet Formulations of Lamotrigine
por: Incecayir, Tuba, et al.
Publicado: (2023)

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020)

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021)

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix
por: Agarwal, Sanjay K, et al.
Publicado: (2021)

Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study
por: Ciceri, Samuele, et al.
Publicado: (2023)

Response to “Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?”
por: Templeton, IE, et al.
Publicado: (2017)

Understanding Dissolution Rates via Continuous Flow Systems with Physiologically Relevant Metal Ion Saturation in Lysosome
por: Keller, Johannes G., et al.
Publicado: (2020)

Lytic Release of Cellular ATP: Physiological Relevance and Therapeutic Applications
por: Grygorczyk, Ryszard, et al.
Publicado: (2021)

Dissolution and pharmacokinetics of a novel micronized aspirin formulation
por: Voelker, M., et al.
Publicado: (2011)

Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
por: Carr, Bruce, et al.
Publicado: (2013)

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
por: Templeton, IE, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_orkotaaiku6d3s94gvbjoftpla